CHRNA1 promotes the pathogenesis of primary focal hyperhidrosis

2021 ◽  
Vol 111 ◽  
pp. 103598 ◽  
Author(s):  
Jian-Bo Lin ◽  
Ming-Qiang Kang ◽  
Li-Ping Huang ◽  
Yi Zhuo ◽  
Xu Li ◽  
...  
Keyword(s):  
Focal Hyperhidrosis

scholarly journals Use of Botulinum Neurotoxin in Parkinson’s Disease: A Critical Appraisal

Toxins ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 87
Author(s):  
Wolfgang H. Jost
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Botulinum Neurotoxin ◽  
Critical Appraisal ◽  
Freezing Of Gait ◽  
Sufficient Data ◽  
Pisa Syndrome ◽  
Focal Hyperhidrosis ◽  
Detrusor Hyperactivity ◽  
Important Indication

For well over 30 years, the botulinum neurotoxin (BoNT) has been used for a large number of indications, some of which however have not been licensed. Admittedly, approval varies in many countries and this permits a large spectrum for evaluation. Thus, BoNT is used for patients with Parkinson’s disease (PD) and other Parkinson’s syndromes (PS) in varying degrees of frequency. We have to distinguish between (1) indications that are either approved or (2) those not approved, (3) indications that might be a result of PS and (4) finally those which appear independent of PS. The most important indication for BoNT in PS patients is probably sialorrhea, for which approval has been granted in the majority of countries. Cervical dystonia is a frequent symptom in PS, with anterocollis as a specific entity. A further indication is blepharospasm in the different forms, especially the inhibition of eyelid opening in atypical PS. The use of BoNT in cases of camptocormia, the Pisa syndrome and neck rigidity is still a matter of debate. In dystonia of the extremities BoNT can be recommended, especially in dystonia of the feet. One well-known indication, for which however sufficient data are still lacking, involves treating tremor with BoNT. As to autonomic symptoms: Focal hyperhidrosis and detrusor hyperactivity can be mentioned, in this last case BoNT has already been approved. A number of further but rare indications such as freezing-of-gait, dyskinesia, and dysphagia will be discussed and evaluated.

Generalized neurological symptoms following treatment of focal hyperhidrosis with botulinum toxin A

2014 ◽  
Vol 53 (11) ◽  
pp. e544-e547 ◽  
Author(s):  
Anargyros Kouris ◽  
Euthymia Agiasofitou ◽  
Stamatios Gregoriou ◽  
Evangelia Sofouri ◽  
Gregorios Panagopoulos ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Neurological Symptoms ◽  
Toxin A ◽  
Focal Hyperhidrosis

Involvement of activin a receptor type 1 (ACVR1) in the pathogenesis of primary focal hyperhidrosis

2020 ◽  
Vol 528 (2) ◽  
pp. 299-304
Author(s):  
Jian-Bo Lin ◽  
Jian-Feng Chen ◽  
Fan-Cai Lai ◽  
Xu Li ◽  
Jin-Bao Xie ◽  
...  
Keyword(s):  
Activin A ◽  
Receptor Type ◽  
Focal Hyperhidrosis

scholarly journals Focal Hyperhidrosis Associated with Recurrent Urinary Tract Infections

2016 ◽  
Vol 2016 ◽  
pp. 1-3
Author(s):  
Dina Ismail ◽  
Vidya Madhwapathi ◽  
Evmorfia Ladoyanni
Keyword(s):  
Urinary Tract ◽  
Interesting Case ◽  
Bladder Pressure ◽  
Excessive Sweating ◽  
Urethral Strictures ◽  
Eccrine Glands ◽  
Tract Infections ◽  
Focal Hyperhidrosis ◽  
Clinical Conditions ◽  
New Onset

Hyperhidrosis affects almost 3% of the population and is characterized by sweating that occurs in excess of that needed for normal thermoregulation. It can occur as a primary disease or secondary to underlying clinical conditions. Hyperhidrosis can stem from neurogenic sympathetic over activity involving normal eccrine glands. We report the interesting case of a 75-year-old male patient with a 6-month history of new onset secondary focal hyperhidrosis of buttocks, pelvis, and upper thighs. Each time his symptoms worsened he was found to have culture positive urine samples forEscherichia coli(E. coli). He underwent urological investigation and was found to have urethral strictures and cystitis. The hyperhidrosis improved each time his urinary tract infection (UTI) was treated with antibiotics and continued to remain stable with a course of prophylactic trimethoprim. We hypothesize that the patient’s urethral strictures led to inhibition in voiding which in turn increased the susceptibility to UTIs. Accumulation of urine and increased bladder pressure in turn raised sympathetic nerve discharge leading to excessive sweating. We recommend that a urine dip form part of the routine assessment of patients presenting with new onset focal hyperhidrosis of pelvis, buttocks, and upper thighs. Timely urological referral should be made for all male patients with recurrent UTI. To the authors’ knowledge, there have been no other reports of UTI-associated focal hyperhidrosis.

Botulinum toxin in the treatment of focal hyperhidrosis

2006 ◽  
Vol 1 (2) ◽  
pp. 217-225 ◽  
Author(s):  
Pelin Kocyigit ◽  
Seher Bostanci
Keyword(s):  
Botulinum Toxin ◽  
Focal Hyperhidrosis

IMPACT OF COMPENSATORY HYPERHIDROSIS ON PATIENT SATISFACTION AFTER ENDOSCOPIC THORACIC SYMPATHECTOMY

Neurosurgery ◽  
2009 ◽  
Vol 64 (3) ◽  
pp. 511-518 ◽  
Author(s):  
Mark Chwajol ◽  
Ignacio J. Barrenechea ◽  
Shamik Chakraborty ◽  
Jonathan B. Lesser ◽  
Cliff P. Connery ◽  
...  
Keyword(s):  
Patient Satisfaction ◽  
Retrospective Chart Review ◽  
Definitive Treatment ◽  
P Value ◽  
Endoscopic Thoracic Sympathectomy ◽  
Compensatory Hyperhidrosis ◽  
Thoracic Sympathectomy ◽  
Level Of Satisfaction ◽  
Focal Hyperhidrosis ◽  
The Impact

Abstract OBJECTIVE Endoscopic thoracic sympathectomy (ETS) remains the definitive treatment for primary focal hyperhidrosis. Compensatory hyperhidrosis (CH) is a significant drawback of ETS. We sought to identify the predictors for the development of severe CH after ETS, its anatomic locations, and its frequency of occurrence, and we analyzed the impact of CH on patient satisfaction with ETS. METHODS Bilateral ETS for primary focal hyperhidrosis was performed in 220 patients, and a retrospective chart review was conducted. Follow-up evaluation was conducted using a telephone questionnaire, and 73% of all patients were contacted. Patients' responses regarding CH and their level of satisfaction after ETS were analyzed. Statistical analysis was performed using SPSS software (Version 14.0; SPSS, Inc., Chicago, IL). A P value of <0.05 was considered statistically significant. RESULTS Some degree of CH developed in 94% of patients. The number of levels treated was not related to the occurrence of severe CH. Isolated T3 ganglionectomy led to a significantly lower incidence of severe CH, when compared with all other levels (P < 0.03). Ninety percent of patients were satisfied with the procedure. The development of severe CH, as opposed to mild or moderate CH, significantly correlated with a lower satisfaction rate (P = 0.003). CONCLUSION CH is common after ETS procedures, and the occurrence of severe, but not mild or moderate, CH is a major source of dissatisfaction after ETS. The overall occurrence of severe CH is reduced after T3 ganglionectomy as opposed to ganglionectomies performed at all other levels. The level of satisfaction with ETS is high.

Heart Rate Variability Assessment and Its Application for Autonomic Function Evaluation in Patients with Hyperhidrosis

2020 ◽  
Vol 83 (3) ◽  
pp. 293-300
Author(s):  
Aracy Satoe Mautari Niwa ◽  
Michele Lima Gregório ◽  
Luiz Eduardo Villaça Leão ◽  
Moacir Fernandes de Godoy
Keyword(s):  
Heart Rate ◽  
Heart Rate Variability ◽  
Nervous System ◽  
Point Of View ◽  
Function Evaluation ◽  
Recurrence Plots ◽  
Time Frequency ◽  
Hrv Analysis ◽  
Focal Hyperhidrosis ◽  
Systemic Component

Background: Pathophysiology mechanism of primary focal hyperhidrosis (PFHH) is controversial. Heart rate variability (HRV) could explain if there is a systemic component present. We aimed to investigate the functions of the autonomic nervous system in patients diagnosed with PFHH compared to controls using the analysis of HRV in the domains of time, frequency, and nonlinearity, as well as analysis of the recurrence plots (RPs). Methods: We selected 34 patients with PFHH (29.4 ± 10.2 years) and 34 controls (29.2 ± 9.6 years) for HRV analysis. Heart beats were recorded with Polar RS800CX monitor (20 min, at rest, in supine position), and RR intervals were analyzed with Kubios Premium HRV software. RPs were constructed with Visual Recurrence Analysis software. Statistical analysis included unpaired t test (p < 0.05). Results: Our results showed that HRV parameters in the 3 domains evaluated did not show any differences between the groups. The same was observed with RPs. Conclusions: The findings suggest that PFHH, from the pathophysiological point of view, may be caused by peripheral involvement of the sympathetic nervous system (glandular level or nerve terminals), as there was no difference between the groups studied. More specific studies should help elucidate this issue.

Sign in / Sign up

Export Citation Format

Share Document